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injection was monitored on real-time ultrasound using the 
probe on the endoscope. Patients were monitored for two 
hours before discharge.  
Daily cone beam CT (CBCT) images and 2D kV fluoroscopy 
(FS) images at fractions 2, 16 and 30 were acquired for setup 
and evaluation of marker visibility.  
Safety visits were planned twice during the RT course. 
 
Results: 15 patients were included. A total of 35 markers 
were injected, 1-3 markers per patient, 0.10-0.30 mL per 
injection.  
The marker injections were performed 9-27 days before start 
of RT  
No pneumothorax, haemorrhage or other serious 
complications to the marker injection were observed during 
or after the procedure.  
29 of 35 placed markers were available for evaluation; 2 
markers disappeared and one dispersed into a tumour cavity.  
Another three markers were injected in two patients who 
subsequently did not receive RT; one patient died (not 
related to the marker) and one patient developed metastatic 
disease prior to start of RT.  
All 29 examined markers remained stable in position relative 
to original injection site (based on visual assessment) and 
were visible on planning CT, CBCT and FS images throughout 
the treatment course (fig.1).  
27 of 29 markers were usable for image registration between 
planning CT and CBCT.  
No marker related adverse events were seen during the RT 
period. 
 
 
Conclusion: The liquid fiducial marker is a safe and clinically 
useful alternative to solid metal fiducial markers for IGRT of 
patients with NSCLC and may also be a good alternative for 
use in IGRT of other solid tumours. 
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Purpose or Objective: Standard of care for patients with 
inoperable, locally advanced non-small-cell lung cancer 
(NSCLC) consists in combined radiochemotherapy (RCT) with 
curative intent. Ideally, radiotherapy planning will be 
performed based on F18-FDG-PET/CT. Additionally, there is 
great interest in using the biological signal from PET/CT for 
assessment of treatment response and outcome prediction. 
Hypothetically, PET/CT may serve as basis for treatment 
modification such as dose escalation of radiotherapy for poor 
responders to RCT. The objective of the presented work was 
the evaluation of the early primary tumor (PT) response 
during RCT by means of response (R)-PET/CTs during and 
shortly after radiotherapy and its correlation with survival. 
 
Material and Methods: Between 2011 – 2015, 39 patients 
with locally advanced NSCLC undergoing conventionally 
fractionated (2 Gy/day) RCT were prospectively scheduled 
for three whole-body PET/CT-scans (a radiotherapy planning 
(RP) PET/CT, a first response PET/CT (1R-PET/CT) 2 weeks 
after start of RCT and a second response PET/CT (2R-PET/CT) 
within one week after end of RCT. FDG-uptake of the PT was 
measured semiquantitatively by means of the maximum 
standardized uptake value (SUVmax). SUVmax measurements 
were compared using PERCIST 1.0 criteria*. Here, a response 
to treatment is defined by a decline of SUVmax of at least 
30% (partial metabolic response, PMR). * Wahl RL, et al.: 
From RECIST to PERCIST: Evolving Considerations for PET 
Response Criteria in Solid Tumors, JNM, Vol. 50, No. 5 
(Suppl), May 2009 
 
Results: 39 patients (33% female, 67% male) with a NSCLC 
(59% SCC, 31% adenocarcinoma and 10% other NSCLC) in 
UICC-stage IIa (5%), IIIa (51%) und IIIb (44%) received an 
average total dose of median 68 (58-76) Gy during a median 
duration of 49 (39-66) irradiation days. Median GTV size was 
58 (15-923) ml. SUVmax was median 14 (5.5-28.3) in the RP-
PET/CT median 15 (2-37) days before start of irradiation. 33 
patients had a 1R-PET/CT median 15 (13-29) days after start 
of irradiation and at median 22 (16-40) Gy, with a SUVmax of 
median 10.5 (3.4-23.7)). 36 patients had a 2R-PET/CT median 
4.5 (4 days before, 15) days after end of irradiation, with a 
SUVmax of median 5.45 (1.4-14.3). A PMR was seen in 14/33 
(42%) patients in the 1R-PET/CT (PMR1) (compared to the RP-
PET/CT), and in 22/30 (73%) patients in the 2R-PET/CT 
(PMR2) (compared to the 1R-PET/CT). 9/29 (31%) patients 
reached both a PMR1 and a PMR2 (double PMR), none of these 
patients experienced a PT-progression during a median follow 
up of 18 (1.4-53) months after end of irradiation. The 2-year-
overall survival rate was 75% as opposed to 54% without a 
double PMR. 
 
Conclusion: These preliminary data imply that a double PMR 
measured in response PET/CTs scheduled during and at the 
end of RCT for NSCLC is associated with a prolonged overall 
survival rate. 
 
PO-0694  
Lung toxicity modelling in thoracic post-operative RT for 
NSCLC and pleural mesothelioma 
A. Botticella
1KU Leuven - University of Leuven- University Hospitals 
Leuven, Laboratory of Experimental Radiotherapy- Oncology 
Department, Leuven, Belgium 
1, G. Defraene1, C. Billiet1, C. Draulans1, K. 
Nackaerts2, C. Deroose3, J. Coolen4, P. Nafteux5, S. Peeters1, 
D. De Ruysscher1 
2KU Leuven - University of Leuven- University Hospitals 
Leuven, Respiratory Diseases/Respiratory Oncology Unit, 
Leuven, Belgium 
3KU Leuven - University of Leuven- University Hospitals 
Leuven, Department Imaging and Pathology- Nuclear 
Medicine and Molecular Imaging, Leuven, Belgium 
4KU Leuven - University of Leuven- University Hospitals 
Leuven, Radiology Department, Leuven, Belgium 
5KU Leuven - University of Leuven- University Hospitals 
Leuven, Department of Thoracic Surgery, Leuven, Belgium 
 
Purpose or Objective: Our hypothesis is that NSCLC patients 
and malignant pleural mesothelioma (MPM) patients treated 
with thoracic post-operative RT (PORT) are more prone to 
develop lung toxicity compared to non-surgical NSCLC RT 
patients. Main objectives are: 1) To quantify the differences 
in terms of CT lung density changes after PORT for NSCLC and 
MPM vs. non-surgical RT patients; and 2) To evaluate the 
correlation between CT lung density changes, dosimetric 
factors and clinical symptoms (dyspnea). 
 
Material and Methods: Two groups of patients were 
analyzed: a) SURGICAL GROUP (n=27): stage I-III resectable 
MPM treated with extrapleural pneumonectomy (EPP) and 
PORT (n=22) and stage I-III NSCLC treated with 
pneumonectomy and PORT (n=5); b) NON-SURGICAL GROUP 
(n=35): stage I-IV NSCLC treated with chemo-radiotherapy. 
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Patients were treated consecutively in the University 
Hospitals of Leuven between 2005 and 2014 and their data 
were retrospectively retrieved. PORT MPM patients were 
treated with RT doses up to 64 Gy in 2-Gy fractions. PORT 
NSCLC were treated with RT doses up to 60 Gy in 2-Gy 
fractions. Non-surgical patients were treated with RT doses 
up to 66 Gy in 2.75 Gy sequentially with chemotherapy or up 
to 70 Gy in 2 Gy fractions concurrently with chemotherapy. 
Dyspnea scores (CTCAE 4.03) before and after RT were 
retrieved and delta dyspnea was calculated as the difference 
between the dyspnea after RT (worse at any time point) and 
before RT. For every patient, 2 CT scans were retrieved: 1) 
CT0: a free breathing planning CT scan; 2) CT3M: deep 
inspiration breath-hold diagnostic follow up CT scan 3-6 
months after the end of RT. CT0 and CT3M were non-rigidly 
co-registered in MIM. Differences in Hounsfield Unit (delta 
HU=HU3M-HU0) were represented as the slope of the dose-
dependent delta HU between 0 and 20 Gy (expressed in delta 
HU/Gy). Primary endpoint was delta dyspnea >= 2. Univariate 
and multivariate logistic regression analysis were performed 
in order to identify significant predictors of delta dyspnea >= 
2. A p-value of < 0.05 was considered statistically significant.  
 
Results: Delta dyspnea >= 2 was observed in 10/27 patients 
(37%) in the surgical group and in 7/35 patients (20%) in the 
non-surgical group (chi-square test 3.38, p=0.06). Mean delta 
HU/Gy was higher in the surgical group (1.63 vs. 0.67, t-test: 
p=0.04) (see Figure 1). Outcomes of univariate and 
multivariate analysis are showed in Table 1. The model with 
MLD, mean delta HU/Gy and mean heart dose appears to 
better predict a delta dyspnea >= 2 both in the surgical and 
non-surgical group (although not significant). 
 
 
 
 
Conclusion: Surgical patients after PORT are at higher risk of 
developing clinically relevant dyspnea (with a delta >= 2) and 
have a higher increase in lung density (a surrogate of lung 
damage) compared with non-surgical patients. To strengthen 
this hypothesis, we will investigate radiation toxicity after 
more limited surgery (lobectomy) in NSCLC patients. Results 
will be available by the time of the congress. 
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Purpose or Objective: Purpose Data from prospective 
randomized clinical trials are lacking in the comparison 
between lobectomy (LOB) and stereotactic ablative 
Radiotherapy (SABR) in operable patients (pts) and on-going 
trials have troubles in recruiting. In inoperable pts SABR 
achieves a local control of 64-95% in retrospective and 92-98% 
in prospective trials particularly when over 100 Gy Biological 
Equivalent Dose (BED) is delivered. 
 
Material and Methods: From 2010 to 2014, 187 pts with stage 
I-II NSCLC were treated: 133 were male, 54 female. Mean age 
was 72 years. Cyto-histological prove of NSCLC was available 
in 167/187 (89.3%): 111 pts had adenocarcinoma, 51 
squamous cell carcinoma and 3 other histologies. 133 pts 
(71.1%) had stage T1 NSCLC, and 54 (29.9%) stage II NSCLC. 
Ninety-three (49.8%) pts underwent SABR, while ninety-four 
(50.2%) were submitted to LOB. Pts who underwent SABR 
received to 9-20 Gy/die for 3-7 fractions; BED was superior 
than 100 Gy for all treatments. Response to SABR was 
evaluated according to RECIST criteria and toxicity according 
to CTCAE 4.0 scale. To compare LOB vs SABR, we analyzed 
outcomes in terms of Local Control (LC), Tumor-Specific 
Survival (TSS), Metastasis Free Survival (MFS) and Overall 
Survival (OS) using Kaplan-Meier method and log rank tests to 
evaluate differences in time-to-event outcomes between LOB 
and SABR. 
 
Results: At a mean follow up of 23 months (range 6-67), LOB 
showed a better OS (p <0,014) with a 2- and 5-yr OS of 
67,6±5,9% and 34.6±15,7% for SABR and 84.1±4.8% and 
73.4±6.6% for LOB. SABR achieved the same results in terms 
of LC with a 2 and a 5 years LC of 92±3.2% and 80.8±7.9% 
respectively with a p<0,07. Neither significant difference in 
frequency of distant metastasis nor in TSS was observed 
between the two treatment groups (respectively p< 0.41 and 
p<0.50).. In SABR group only 3 G3 lung toxicities were found. 
No other G3 or G4 acute/late toxicity was found. Toxicity 
was minor in SABR group (1 fatigue G1,1 dyspnoea G1,1 
hemoptysis G1); in surgery group we have recorded 7 atrial 
fibrillation, 2 bleeding,1 with death, e 6 prolonged air leak. 
 
Conclusion: SABR using high doses (BED>100) shows similar 
LC than LOB. Very encouraging results in terms of MFS and 
TSS with very few toxicity and no excess of tumor-related 
deaths are obtained with SABR compared with LOB. OS is 
better in LOB group, apparently being strongly influenced by 
the selection of pts addressed to surgery. 
 
Poster: Clinical track: Upper GI (oesophagus, stomach, 
pancreas, liver)  
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Purpose or Objective: Most of trials which established the 
standard treatment of locally advanced oesophageal cancer 
included M0 stage according to the 6th edition of the AJCC 
staging system. Now in the 7th edition of AJCC staging 
system, supraclavicular and celiac lymph node (LN) 
metastasis are no more classified into M1, but considered 
same as other regional LNs. We aimed to evaluate the 
treatment outcomes of NACRT followed by surgery in thoracic 
